<DOC>
	<DOCNO>NCT02297516</DOCNO>
	<brief_summary>The efficacy safety , well subject satisfaction evaluate single treatment Azzalure/Dysport alone Restylane/Emervel filler alone follow repeated combined treatment Azzalure/Dysport , Restylane/Emervel filler Restylane Skinbooster . Subjects follow 18 month initial treatment .</brief_summary>
	<brief_title>Safety Efficacy Azzalure/Dysport , Restylane/Emervel Filler Restylane Skinbooster Treatment</brief_title>
	<detailed_description />
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Inclusion Criteria Subjects age 35 50 year old Subjects intention undergo facial aesthetic treatment likely benefit combination injection treatment benefit show improvement global facial aesthetic appearance satisfaction . Subjects nasolabial fold assess mild moderate . Subjects upper facial line treat ( least two glabellar line , crowÂ´s foot and/or forehead line ) assess moderate severe , severity line important psychological impact subject . Subjects sign informed consent . Obvious facial sagging ( major loss facial fat/volume ) . Signs symptoms eyelid ptosis sign compensatory frontalis muscle activity . Heavily scar sundamaged facial skin . Active skin disease , inflammation related condition , infection , psoriasis herpes zoster/herpes simplex near area treat . Cancerous precancerous lesion area treat . Facial tissue augment therapy revitalization treatment hyaluronic acid ( HA ) collagen , botulinum toxin treatment last 12 month . Procedures treatment induce active dermal response laser , Intense Pulsed Light , chemical peeling , microdermabrasion , retinoids within last 6 month . Any aesthetic surgery face . Permanent implant aesthetic treatment nonHA noncollagen product face . History severe keloid and/or hypertrophic scar . Neuromuscular junctional disorder ( e.g . myasthenia gravis , Eaton Lambert syndrome amyotrophic lateral sclerosis ) history dysphagia aspiration . Known hypersensitivity hyaluronic acid , botulinum toxin , lidocaine hydrochloride amidetype anesthetic . History autoimmune disease . Any medical condition opinion investigator would make subject unsuitable inclusion ( e.g . chronic , relapse hereditary disease may affect general condition may require frequent medical treatment ) . Concomitant anticoagulant therapy therapy inhibitor platelet aggregation ( e.g . aspirin nonsteroidal antiinflammatory drug [ NSAIDs ] ) , Omega3 vitamin E within 10 day study treatment , history bleeding disorder . Immunosuppressive therapy , chemotherapy , systemic corticosteroid within last 3 month prior baseline visit . Female subject pregnant plan become pregnant within study timeframe , nursing .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>